Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity

Launched by HUNAN CHILDREN'S HOSPITAL · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to diagnose and monitor a condition called metabolic bone disease of prematurity (MBDP), which affects some preterm infants due to their bones not getting enough important nutrients. The researchers are focusing on tiny particles called exosomes that carry specific microRNAs, which are small molecules that can indicate how well the bones are developing. By examining these microRNAs in the blood of preterm infants, the study aims to find a more reliable and earlier way to detect MBDP, which could lead to better treatment and outcomes for these vulnerable babies.

To participate in this trial, infants must be between 0 and 28 days old, born between 37 and 42 weeks of pregnancy. They cannot have had a blood transfusion, surgery, or any congenital (birth) defects. If eligible, participants will provide blood samples, which will be analyzed to see if the microRNAs can effectively signal the presence and severity of MBDP. The findings could not only help improve the health of these infants but also reduce healthcare costs associated with treating complications from this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The gestational age was 37+0-41+6 weeks and the age was less than 28 days
• Exclusion Criteria:
• • There was no blood transfusion, no operation, no congenital malformation, no inherited metabolic diseases, no history of intravenous nutrition, and no intestinal diseases